A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
M34103-061
NCT00085696
May 2004
Name | Location |
---|---|
MD Anderson Cancer Center | Houston, Texas 77030-4096 |
UCLA School of Medicine | Los Angeles, California 900121973 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Georgia Cancer Specialists | Decatur, Georgia 30033 |
Florida Cancer Specialists | Fort Myers, Florida 33901 |
Charleston Cancer Center | Charleston, South Carolina 29406 |
Midwest Cancer Research Group | Skokie, Illinois 60077 |
University of Utah, Huntsman Cancer Institute | Salt Lake City, Utah 84112 |
Emory University Cancer Institute, Winship Cancer Institute | Atlanta, Georgia 30322 |
Cancer Center of Kansas | Wichita, Kansas 67214 |
Oncology/Henmatology Associates of Kansas City | Kansas City, Missouri 64111 |
Mid Ohio Oncology/Hematology Inc. | Columbus, Ohio 43213 |
FNVHO - US Oncology | Fairfax, Virginia 20031 |